Retigabine/Ezogabine, a KCNQ/K_V7 channel opener: pharmacological and clinical data

Bibliography

• Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol 2003;16:165-70
   PubMed Web of Science ®Google Scholar
• Brodie MJ, French JA. Management of epilepsy in adolescents and adults. Lancet 2000;356:323-9
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Definition of refractory epilepsy: defining the indefinable? Lancet Neurol 2010;9:27-9
   PubMed Web of Science ®Google Scholar
• Wang HS, Pan Z, Shi W, KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science 1998;282:1890-3
   PubMed Web of Science ®Google Scholar
• Delmas P, Brown DA. Pathways modulating neural kcnq/m KV7 potassium channels. Nat Rev Neurosci 2005;6:850-62
   PubMed Web of Science ®Google Scholar
• Maljevic S, Wuttke TV, Seebohm G, KV7 channelopathies. Pflugers Arch 2010;460:277-88
   Google Scholar
• Aiken SP, Lampe BJ, Murphy PA, Reduction of spike frequency adaptation and blockade of M-current in rat CA1 pyramidal neurones by linopirdine (DuP 996), a neurotransmitter release enhancer. Br J Pharmacol 1995;115:1163-8
   PubMed Web of Science ®Google Scholar
• Friedel HA, Fitton A. Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states. Drugs 1993;45:548-69
   Google Scholar
• Rostock A, Tober C, Rundfeldt C, D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 1996;23:211-23
   PubMed Web of Science ®Google Scholar
• Tober C, Rostock A, Rundfeldt C, D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 1996;303:163-9
   PubMed Web of Science ®Google Scholar
• Armand V, Rundfeldt C, Heinemann U. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices. Naunyn Schmiedebergs Arch Pharmacol 1999;359:33-9
   PubMedGoogle Scholar
• Armand V, Rundfeldt C, Heinemann U. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices. Epilepsia 2000;41:28-33
   PubMed Web of Science ®Google Scholar
• Dost R, Rundfeldt C. The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca2+ and low Mg2+ model in the hippocampal slice preparation. Epilepsy Res 2000;38:53-66
   PubMed Web of Science ®Google Scholar
• Straub H, Kohling R, Hohling J, Effects of retigabine on rhythmic synchronous activity of human neocortical slices. Epilepsy Res 2001;44:155-65
   PubMed Web of Science ®Google Scholar
• Otto JF, Yang Y, Frankel WN, Mice carrying the szt1 mutation exhibit increased seizure susceptibility and altered sensitivity to compounds acting at the m-channel. Epilepsia 2004;45:1009-16
   PubMed Web of Science ®Google Scholar
• Luszczki JJ, Wu JZ, Raszewski G, Czuczwar SJ. Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model. Naunyn Schmiedebergs Arch Pharmacol 2009;379:163-79
   PubMed Web of Science ®Google Scholar
• Surti TS, Jan LY. A potassium channel, the M-channel, as a therapeutic target. Curr Opin Investig Drugs 2005;6:704-11
   PubMedGoogle Scholar
• Blackburn-Munro G, Jensen BS. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur J Pharmacol 2003;460:109-16
   PubMed Web of Science ®Google Scholar
• Hansen HH, Andreasen JT, Weikop P, The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine. Eur J Pharmacol 2007;570:77-88
   PubMedGoogle Scholar
• Gongadze N, Antelava N, Kezeli T, The mechanisms of neurodegenerative processes and current pharmacotherapy of Alzheimer's disease. Georgian Med News 2008;155:44-8
   Google Scholar
• Rundfeldt C. Characterization of the K+ channel opening effect of the anticonvulsant retigabine in pc12 cells. Epilepsy Res 1999;35:99-107
   PubMed Web of Science ®Google Scholar
• Rundfeldt C, Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci Lett 2000B;282:73-6
   PubMed Web of Science ®Google Scholar
• Wickenden AD, Yu W, Zou A, Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 2000;58:591-600
   PubMed Web of Science ®Google Scholar
• Main MJ, Cryan JE, Dupere JR, Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine Mol Pharmacol 2000;58:253-62
   Google Scholar
• Tatulian L, Delmas P, Abogadie FC, Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci 2001;21:5535-45
   PubMed Web of Science ®Google Scholar
• Delmas P, Brown DA. Pathways modulating neural kcnq/m (KV7) potassium channels. Nat Rev Neurosci 2005;6:850-62
   PubMed Web of Science ®Google Scholar
• Maljevic S, Wuttke TV, Seebohm G, KV7 channelopathies. Pflugers Arch 2010;460:277-88
   Google Scholar
• Jentsch TJ. Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci 2000;1:21-30
   PubMed Web of Science ®Google Scholar
• Wuttke TV, Seebohm G, Bail S, The new anticonvulsant retigabine favors voltage-dependent opening of the KV7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol 2005;67:1009-17
   PubMed Web of Science ®Google Scholar
• Schenzer A, Friedrich T, Pusch M, Molecular determinants of KCNQ (KV7) K+ channel sensitivity to the anticonvulsant retigabine. J Neurosci 2005;25:5051-60
   PubMed Web of Science ®Google Scholar
• Lange W, Geissendorfer J, Schenzer A, Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels. Mol Pharmacol 2009;75:272-80
   PubMedGoogle Scholar
• Otto JF, Kimball MM, Wilcox KS. Effects of the anticonvulsant retigabine on cultured cortical neurons: changes in electroresponsive properties and synaptic transmission. Mol Pharmacol 2002;61:921-7
   PubMed Web of Science ®Google Scholar
• Rundfeldt C, Netzer R. Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung 2000A;50:1063-70
   Google Scholar
• Hermann R, Knebel NG, Niebch G, Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Eur J Clin Pharmacol 2003A;58:795-802
   PubMed Web of Science ®Google Scholar
• Ferron GM, Paul J, Fruncillo R, Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol 2002;42:175-82
   PubMed Web of Science ®Google Scholar
• Hermann R, Ferron GM, Erb K, Effects of age and sex on the disposition of retigabine. Clin Pharmacol Ther 2003B;73:61-70
   PubMedGoogle Scholar
• Ferron GM, Patat A, Parks V, Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. Br J Clin Pharmacol 2003;56:39-45
   PubMed Web of Science ®Google Scholar
• Hammond JMJ. Retigabine. In: Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS, Epilepsy Res 2010;92:113-16
   Google Scholar
• Mansbach H. Retigabine. In: Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS, Epilepsy Res 2009;83:27-31
   Google Scholar
• Ferron GM, Sachdeo R, Partiot A, Pharmacokinetic interaction between valproic acid, topiramate, phenytoin or carbamazepine and retigabine in epileptic patients. Clin Pharmacol Ther 2001;69:P18
   Google Scholar
• McNeilly PJ, Torchin CD, Anderson LW, In vitro glucuronidation of D-23129, a new anticonvulsant, by human liver microsomes and liver slices. Xenobiotica 1997;27:431-41
   PubMed Web of Science ®Google Scholar
• Hempel R, Schupke H, McNeilly PJ, Metabolism of retigabine (D-23129), a novel anticonvulsant. Drug Metab Dispos 1999;27:613-22
   PubMed Web of Science ®Google Scholar
• Hiller A, Nguyen N, Strassburg CP, Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos 1999;27:605-12
   PubMed Web of Science ®Google Scholar
• Borlak J, Gasparic A, Locher M, N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II. Metabolism 2006;55:711-21
   PubMedGoogle Scholar
• Hermann R, Borlak J, Munzel U, The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine. Pharmacogenomics 2006;6:211-19
   Google Scholar
• French J, Porter A, Nohria V. Retigabine. In: Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T, Epilepsy Res 2004;61:10-12
   Google Scholar
• Porter RJ, Partiot A, Sachdeo R, Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007;68:1197-204
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Lerche H, Gil-Nagel A, Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010;75:1817-24
   PubMed Web of Science ®Google Scholar
• French JA, Abou-Khalil BW, Leroy RF, Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 2011;76:1555-63
   PubMed Web of Science ®Google Scholar
• Brickel N, Gandhi P, Vanlandingham K, The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (Kv7) potassium channels. Epilepsia 2012;53:606-12
   PubMed Web of Science ®Google Scholar
• Katz R. Advisory Committee Meeting to Discuss Antiepileptic Drugs (AEDs) and Suicidality. Memorandum. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA-Katz.pdf) 2008
   Google Scholar
• Arana A, Wentworth CE, Ayuso-Mateos JL, Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med 2010;363:542-51
   PubMed Web of Science ®Google Scholar
• Wickenden AD, Zou A, Wagoner PK, Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells. Br J Pharmacol 2001;132:381-4
   PubMed Web of Science ®Google Scholar
• Perucca E. An introduction to antiepileptic drugs. Epilepsia 2005;46:31-7
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res 1997;26:423-32
   PubMed Web of Science ®Google Scholar
• Pisani F, Oteri G, Russo MF, The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999;40:1141-6
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Covanis A, Gil-Nagel A, Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav 2011;21:331-41
   PubMed Web of Science ®Google Scholar
• Streng T, Christoph T, Andersson KE. Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats. J Urol 2004;72:2054-8
   Google Scholar